INTRODUCTION:beta-Blockers are known to worsen FEV(1) and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring beta-blocker treatment. OBJECTIVE: To determine the effects of beta-blockers on AHR (provocative concentration of methacholine causing a 20% fall in FEV(1) [PC(20)]), FEV(1), and response to formoterol in patients with COPD. DESIGN: A double-blind, placebo-controlled, randomized, cross-over study. SETTING:An ambulatory, hospital outpatient clinic of pulmonary diseases. PATIENTS: Patients with mild-to-moderate irreversible COPD and AHR. INTERVENTION: Fifteen patients received propranolol (80 mg), metoprolol (100 mg), celiprolol (200 mg), or placebo for 4 days, followed by a washout period >/= 3 days. On day 4 of treatment, FEV(1) and PC(20) were assessed. Immediately hereafter, formoterol (12 microg) was administered and FEV(1) was measured for up to 30 min. RESULTS: PC(20) was significantly lower (p < 0.01) with propranolol and metoprolol treatment (geometric means, 2.06 mg/mL and 2.02 mg/mL, respectively) than with placebo (3.16 mg/mL) or celiprolol (3.41 mg/mL). FEV(1) deteriorated only after propranolol treatment (2.08 +/- 0.31 L) [mean +/- SD] compared with placebo (2.24 +/- 0.37 L). The fast bronchodilating effect of formoterol was hampered by propranolol (mean increase in FEV(1) at 3 min, 6.7 +/- 8.9%) but was unaffected by the other beta-blockers (16.9 +/- 9.8%, 22 +/- 11.6%, and 16.9 +/- 9.0% for placebo, metoprolol, and celiprolol, respectively). CONCLUSIONS: Pulmonary effects did not occur by celiprolol. Only propranolol reduced FEV(1) and the bronchodilating effect of formoterol. Both metoprolol and propranolol increased AHR. Thus, different classes of beta-blockers have different pulmonary effects. The anticipated beneficial cardiovascular effects of a beta-blocker must be weighted against the putative detrimental pulmonary effects, ie, effect on FEV(1), AHR, and response to additional beta(2)-agonists.
RCT Entities:
INTRODUCTION: beta-Blockers are known to worsen FEV(1) and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring beta-blocker treatment. OBJECTIVE: To determine the effects of beta-blockers on AHR (provocative concentration of methacholine causing a 20% fall in FEV(1) [PC(20)]), FEV(1), and response to formoterol in patients with COPD. DESIGN: A double-blind, placebo-controlled, randomized, cross-over study. SETTING: An ambulatory, hospital outpatient clinic of pulmonary diseases. PATIENTS: Patients with mild-to-moderate irreversible COPD and AHR. INTERVENTION: Fifteen patients received propranolol (80 mg), metoprolol (100 mg), celiprolol (200 mg), or placebo for 4 days, followed by a washout period >/= 3 days. On day 4 of treatment, FEV(1) and PC(20) were assessed. Immediately hereafter, formoterol (12 microg) was administered and FEV(1) was measured for up to 30 min. RESULTS: PC(20) was significantly lower (p < 0.01) with propranolol and metoprolol treatment (geometric means, 2.06 mg/mL and 2.02 mg/mL, respectively) than with placebo (3.16 mg/mL) or celiprolol (3.41 mg/mL). FEV(1) deteriorated only after propranolol treatment (2.08 +/- 0.31 L) [mean +/- SD] compared with placebo (2.24 +/- 0.37 L). The fast bronchodilating effect of formoterol was hampered by propranolol (mean increase in FEV(1) at 3 min, 6.7 +/- 8.9%) but was unaffected by the other beta-blockers (16.9 +/- 9.8%, 22 +/- 11.6%, and 16.9 +/- 9.0% for placebo, metoprolol, and celiprolol, respectively). CONCLUSIONS: Pulmonary effects did not occur by celiprolol. Only propranolol reduced FEV(1) and the bronchodilating effect of formoterol. Both metoprolol and propranolol increased AHR. Thus, different classes of beta-blockers have different pulmonary effects. The anticipated beneficial cardiovascular effects of a beta-blocker must be weighted against the putative detrimental pulmonary effects, ie, effect on FEV(1), AHR, and response to additional beta(2)-agonists.
Authors: Princy Thottathil; Jay Acharya; Arthur J Moss; Christian Jons; Scott McNitt; Ilan Goldenberg; Wojciech Zareba; Elizabeth Kaufman; Ming Qi; Jennifer L Robinson Journal: Am J Cardiol Date: 2008-07-17 Impact factor: 2.778
Authors: David S H Lee; Sheila Markwardt; Gail J McAvay; Cary P Gross; Leah M Goeres; Ling Han; Peter Peduzzi; Haiqun Lin; John A Dodson; Mary E Tinetti Journal: Med Care Date: 2014-03 Impact factor: 2.983
Authors: Mark T Dransfield; Helen Voelker; Surya P Bhatt; Keith Brenner; Richard Casaburi; Carolyn E Come; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Umur Hatipoğlu; Erika S Helgeson; Vipul V Jain; Ravi Kalhan; David Kaminsky; Robert Kaner; Ken M Kunisaki; Allison A Lambert; Matthew R Lammi; Sarah Lindberg; Barry J Make; Fernando J Martinez; Charlene McEvoy; Ralph J Panos; Robert M Reed; Paul D Scanlon; Frank C Sciurba; Anthony Smith; Peruvemba S Sriram; William W Stringer; Jeremy A Weingarten; J Michael Wells; Elizabeth Westfall; Stephen C Lazarus; John E Connett Journal: N Engl J Med Date: 2019-10-20 Impact factor: 91.245
Authors: Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield Journal: Thorax Date: 2015-08-17 Impact factor: 9.139